There are currently 679 clinical trials in Orlando, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including AdventHealth Orlando, GSK Investigational Site, Orlando Clinical Research Center and Nemours Children's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
NCT06372964
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
07/26/2024
Locations: Clinical Site, Orlando, Florida
Conditions: Bipolar Depression
Register for Updates
Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania
NCT06462586
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/26/2024
Locations: Clinical Site, Orlando, Florida
Conditions: Bipolar Disorder, Manic
Register for Updates
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
NCT05975983
Recruiting
The goal of this clinical trial is to learn about INS018_055 in adults with Idiopathic Pulmonary Fibrosis (IPF). The primary objective is to evaluate the safety and tolerability of INS018_055 orally administered for up to 12 weeks in adult subjects with IPF compared to placebo.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/25/2024
Locations: Central Florida Pulmonary Group, P.A. (CFPG) - Downtown Orlando, Orlando, Florida
Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Register for Updates
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
NCT05507216
Recruiting
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrin... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
07/25/2024
Locations: Arnold Palmer Hospital For Children, Orlando, Florida +1 locations
Conditions: Ulcerative Colitis
Register for Updates
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
NCT05507203
Recruiting
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrin... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
07/25/2024
Locations: Endoscopic Research, Inc., Orlando, Florida +1 locations
Conditions: Ulcerative Colitis
Register for Updates
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
07/23/2024
Locations: Research Site, Orlando, Florida +2 locations
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Register for Updates
Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
NCT05520099
Recruiting
The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform across a basket of solid tumors, using in-vivo RECIST 1.1 as the reference method.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2024
Locations: AdventHealth Orlando, Orlando, Florida
Conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Endometrial Cancer, Colorectal Cancer, Cutaneous Melanoma, Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma
Register for Updates
Prospective Clinical Registry Evaluating Contemporary MANTA Outcomes
NCT05936996
Recruiting
This is an observational study designed to evaluate the safety and clinical outcomes of the MANTA® Vascular Closure Device (VCD) (the MANTA® Device) in TAVR procedures. The study will enroll participants who are undergoing a TAVR procedure. The purpose of this study is to examine and collect data on outcomes of contemporary MANTA® large bore closure in standard of care (SOC) TAVR procedures with on-label use of the MANTA® device including appropriate patient selection and proper vascular access. Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
07/16/2024
Locations: Orlando Health, Inc, Orlando, Florida
Conditions: Femoral Arteriotomy Closure
Register for Updates
A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment
NCT06318676
Recruiting
The purpose of this study is to evaluate the drug levels of mezigdomide in participants with renal impairment.
Gender:
ALL
Ages:
Between 18 years and 82 years
Trial Updated:
07/11/2024
Locations: Omega Research Group - Orlando, Orlando, Florida +1 locations
Conditions: Renal Impairment
Register for Updates
A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment
NCT06352528
Recruiting
The purpose of this study is to assess the drug levels of a single oral dose of repotrectinib in participants with moderate and severe HI, and in healthy matched control participants with normal hepatic function.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/10/2024
Locations: Local Institution - 0005, Orlando, Florida +1 locations
Conditions: Hepatic Impairment, Healthy Volunteers
Register for Updates
Using a mHealth Intervention to Promote Physical Activity in Phase III Cardiac Rehabilitation Clients
NCT05795036
Recruiting
In this study, the investigators will implement a pilot project of using activity tracker (i.e., Fitbit) with phase III CR clients. The study will record the participants' daily steps and sleep patterns for 8 consecutive weeks in natural settings. Two specific aims are identified for this project: 1. Develop an intervention protocol using mHealth to promote Phase III CR clients' self-monitoring of PA. 2. Examine the efficacy of the intervention on clients' PA, sleep patterns, functional capacit... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/10/2024
Locations: AdventHealth University, Orlando, Florida
Conditions: Cardiac Rehabilitation, Physical Activity
Register for Updates
Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.
NCT05267613
Recruiting
The aim of the study is to compare the safety and efficacy of two doses of Nexium in maintaining healing of erosive esophagitis in patients 1 to 11 years of age.
Gender:
ALL
Ages:
Between 1 year and 11 years
Trial Updated:
07/08/2024
Locations: Research Site, Orlando, Florida
Conditions: Erosive Esophagitis
Register for Updates